Many people still assume that treating acute lymphoblastic leukemia always means months of intensive chemotherapy.

That's becoming less true for some patients.

Over the past few years, targeted immunotherapies such as blinatumomab and inotuzumab ozogamicin have changed the treatment landscape for B-cell ALL.

Rather than attacking rapidly dividing cells throughout the body, these therapies specifically recognize leukemia cells. Blinatumomab redirects the patient's own T cells toward CD19-positive leukemia cells, while inotuzumab delivers a cytotoxic agent directly to CD22-expressing cells.

Several clinical studies have shown impressive remission rates, particularly in relapsed or refractory B-cell ALL. More recently, researchers have also been exploring chemotherapy-reduced and, in selected settings, chemotherapy-free treatment strategies using these agents.

That said, these approaches are not appropriate for every patient. Eligibility depends on factors such as disease subtype, treatment history, age, and overall clinical condition.

It will be interesting to see whether chemotherapy-free regimens eventually become standard for selected patients with B-cell ALL, especially as longer-term outcome data continue to emerge.

How do you think these targeted therapies will reshape frontline treatment over the next decade?